Phase I clinical trials of amphiphilic cholesterol-modified pullulan nanogels carrying a truncated HER2 protein have been conducted as cancer vaccination via a T-cell immune response and antibody response against HER2 [202,203]. This evidence concerns the gene ERBB2 and cancer.